Reid Hoffman is stepping down from Microsoft's board to dedicate himself full-time to Manus, his AI-powered drug discovery startup. The move marks a significant personal pivot for the LinkedIn cofounder, who has served on Microsoft's board for over a decade and benefited substantially from his equity stake during the company's cloud and AI boom.
Hoffman's departure underscores the intensity required to scale an AI biotech venture. Manus applies machine learning to accelerate drug discovery and development, a sector attracting billions in venture capital as computational biology reshapes pharmaceutical R&D. The startup competes in a crowded field that includes companies like Exscientia, Recursion Pharmaceuticals, and others racing to prove AI can meaningfully reduce the decade-long drug development timeline.
The decision reflects broader patterns in founder behavior. As AI disrupts multiple industries simultaneously, established investors are choosing to go "founder mode" on bets they believe could reshape healthcare. For Hoffman, the Microsoft board position represented significant capital accumulation and network access, but Manus apparently represents where he believes the next major wealth creation opportunity lies.
Hoffman brings substantial credibility to Manus. His track record building LinkedIn into a $26 billion acquisition by Microsoft, combined with his portfolio of investments through Greylock Partners, positions him to recruit top talent and secure follow-on funding. His presence as a working founder rather than a board director likely strengthens Manus's ability to recruit researchers and clinical partners.
The timing matters. Microsoft's valuation has matured substantially, reducing the upside potential from board equity. Conversely, drug discovery AI startups remain in early growth phases with dramatically higher risk and return profiles. For founders with Hoffman's resources and network, the asymmetric risk-reward calculation tilts toward building new companies in rapidly expanding fields.
This move signals confidence in Manus